The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.
 
Claire Palles
Patents, Royalties, Other Intellectual Property - Oxford University Innovation and Birmingham Enterprise
 
Marie Lucas
Patents, Royalties, Other Intellectual Property - Oxford University Innovation and Birmingham Enterprise
 
Katie Watts
No Relationships to Disclose
 
Sara Galavotti
Patents, Royalties, Other Intellectual Property - Oxford University Innovation
 
Ik Shin Chin
No Relationships to Disclose
 
Cameron Campbell
No Relationships to Disclose
 
Sarah E W Briggs
No Relationships to Disclose
 
Emma Jaeger
No Relationships to Disclose
 
David Church
No Relationships to Disclose
 
Karen Taylor
Research Funding - Exact Sciences
 
Judith Bliss
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline/Novartis (Inst); Janssen-Cilag (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pfizer
 
David Fisher
No Relationships to Disclose
 
Ayman Madi
No Relationships to Disclose
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
 
Timothy S. Maughan
Consulting or Advisory Role - AstraZeneca/MedImmune; Ground Truth Laboratories; Nordic Bioscience; Nordic Bioscience; Perspectum Diagnostics
Research Funding - Almac Diagnostics (Inst); AstraZeneca (Inst); Merck KgAA (Inst); PsiOxus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - patent pending
 
Ian Tomlinson
No Relationships to Disclose
 
Timothy Iveson
Honoraria - Amgen; SERVIER
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; SERVIER
 
David James Kerr
Employment - Celleron Therapeutics
Leadership - Oxford cancer biomarkers
Stock and Other Ownership Interests - cancer care commission; Celleron Therapeutics; Oxford cancer biomarkers
Consulting or Advisory Role - Geno Bio; Indivumed; Medscape
Speakers' Bureau - Novartis
Patents, Royalties, Other Intellectual Property - patents pending on two biomarker tests developed for Oxford Cancer Biomarkers
 
Rachel Kerr
No Relationships to Disclose
 
Jeremy Cheadle
No Relationships to Disclose